The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
Canopy offers products and services for gene editing, gene expression analysis and regulation, and bioprocessing, as well as a multi-omic immune profiling platform.
Maple Grove, Minnesota-based Stemonix will merge in an all-equity transaction with a newly formed subsidiary of Cancer Genetics, which expects to remain listed on the Nasdaq.
The deal consists of cash, Bionano common stock, and assumption of liabilities. Bionano has also paid off $1.1 million loaned to Lineagen under the CARES act.
Boston-based Cellink will acquire the German firm for €40 million in cash and 2,814,032 newly issued shares valued at €40 million at a price of SEK 146.6 per share.
